| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA767: Ponesimod for treating relapsing–remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | ponesimod (Ponvory®) |
| Formulation | 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 20mg film coated tablets |
| Reference number | 1453 |
| Indication | Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/04/2021 |
| NICE guidance | TA767: Ponesimod for treating relapsing–remitting multiple sclerosis |